Limits...
Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer.

Apostolou P, Toloudi M, Kourtidou E, Mimikakou G, Vlachou I, Chatziioannou M, Papasotiriou I - J Biol Res (Thessalon) (2014)

Bottom Line: Determination of response to chemotherapy is a major requirement of personalized medicine.Resistance, whether developed or native, critically affects a treatment's success.The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

View Article: PubMed Central - PubMed

Affiliation: Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina Greece.

ABSTRACT

Background: Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment's success. Single Cell Gel lectrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer.

Results: We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types.

Conclusion: The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

No MeSH data available.


Related in: MedlinePlus

Comet assay data for cancer cell lines representing colorectal cancer. A: Control HCT-15 cell line without cisplatin. B: HCT-15 after incubation with cisplatin. C: Untreated HCT-116 cell line. D: HCT-116 with cisplatin. E: LoVo cancer cell line without addition of drugs. F: The percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4389674&req=5

Fig2: Comet assay data for cancer cell lines representing colorectal cancer. A: Control HCT-15 cell line without cisplatin. B: HCT-15 after incubation with cisplatin. C: Untreated HCT-116 cell line. D: HCT-116 with cisplatin. E: LoVo cancer cell line without addition of drugs. F: The percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.

Mentions: Analysis of results was based on percentages of DNA in the comet “head” (amount of genetic material distributed in the nucleus) and in “tail” (amount of genetic material distributed in the fragmented pieces). We examined ≥ 100 cells for each combination of cells and drugs. With p set to be 0.05, we estimated the ranges of DNA percentage in untreated and treated cells; where these ranges overlapped, the cells were rejected. In the MCF-7 and MDA-MB 231 cell lines, we clearly observed functional activity for all drugs. The T47D cells showed functional activity for melphalan and doxorubicin, but not for mechlorethamine. All the colorectal cancer cell lines except LoVo, were also successfully affected (Tables 1, 2, 3 and 4; Figures 1, 2 and 3).Figure 1


Use of the comet assay technique for quick and reliable prediction of in vitro response to chemotherapeutics in breast and colon cancer.

Apostolou P, Toloudi M, Kourtidou E, Mimikakou G, Vlachou I, Chatziioannou M, Papasotiriou I - J Biol Res (Thessalon) (2014)

Comet assay data for cancer cell lines representing colorectal cancer. A: Control HCT-15 cell line without cisplatin. B: HCT-15 after incubation with cisplatin. C: Untreated HCT-116 cell line. D: HCT-116 with cisplatin. E: LoVo cancer cell line without addition of drugs. F: The percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4389674&req=5

Fig2: Comet assay data for cancer cell lines representing colorectal cancer. A: Control HCT-15 cell line without cisplatin. B: HCT-15 after incubation with cisplatin. C: Untreated HCT-116 cell line. D: HCT-116 with cisplatin. E: LoVo cancer cell line without addition of drugs. F: The percentage of DNA in tail is reduced after cisplatin incubation; however the data are not significant.
Mentions: Analysis of results was based on percentages of DNA in the comet “head” (amount of genetic material distributed in the nucleus) and in “tail” (amount of genetic material distributed in the fragmented pieces). We examined ≥ 100 cells for each combination of cells and drugs. With p set to be 0.05, we estimated the ranges of DNA percentage in untreated and treated cells; where these ranges overlapped, the cells were rejected. In the MCF-7 and MDA-MB 231 cell lines, we clearly observed functional activity for all drugs. The T47D cells showed functional activity for melphalan and doxorubicin, but not for mechlorethamine. All the colorectal cancer cell lines except LoVo, were also successfully affected (Tables 1, 2, 3 and 4; Figures 1, 2 and 3).Figure 1

Bottom Line: Determination of response to chemotherapy is a major requirement of personalized medicine.Resistance, whether developed or native, critically affects a treatment's success.The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

View Article: PubMed Central - PubMed

Affiliation: Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina Greece.

ABSTRACT

Background: Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment's success. Single Cell Gel lectrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer.

Results: We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types.

Conclusion: The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.

No MeSH data available.


Related in: MedlinePlus